Expand OTLK Menu
OTLK MENU

OTLK Latest Press Releases

-- May 28, 2024 --

Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD Globe Newswire 8:05 AM

-- May 15, 2024 --

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update Globe Newswire 5:00 PM

-- May 13, 2024 --

Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD Globe Newswire 8:50 AM

-- May 9, 2024 --

Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast Globe Newswire 8:45 AM

-- May 2, 2024 --

Outlook Therapeutics to Present at the Retina World Congress 2024 Globe Newswire 9:05 AM

-- April 29, 2024 --

Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase Globe Newswire 9:00 AM

-- April 15, 2024 --

Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million Globe Newswire 4:15 PM

-- March 22, 2024 --

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD Globe Newswire 7:35 AM

-- March 18, 2024 --

Outlook Therapeutics Announces Closing of Private Placement of up to $159 Million Globe Newswire 5:10 PM

-- March 12, 2024 --

Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split Globe Newswire 8:05 AM

-- February 15, 2024 --

Kaskela Law LLC Announces Shareholder Investigation of Outlook Therapeutics, Inc. (OTLK) and Encourages Investors to Contact the Firm Globe Newswire 8:00 AM

-- February 14, 2024 --

Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update Globe Newswire 8:05 AM

-- January 31, 2024 --

Outlook Therapeutics Doses First Subject in NORSE EIGHT Globe Newswire 8:05 AM

-- January 23, 2024 --

Outlook Therapeutics Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 Globe Newswire 8:00 AM

-- January 2, 2024 --

Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm Globe Newswire 10:18 PM
OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK PRNewswire 2:30 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline OTLK Globe Newswire 10:50 AM
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Globe Newswire 10:45 AM
OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! Globe Newswire 9:00 AM
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline PRNewswire 5:45 AM